<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110314006065N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-31</date_registration>
      <primary_sponsor>Development of Medical Research in Iran</primary_sponsor>
      <public_title>Anti-inflammatory diets &amp; mental health</public_title>
      <acronym></acronym>
      <scientific_title>The effects of anti-inflammatory diet alone or in combination with acupuncture on mental health, advanced glycation end products (AGEs), anthropometric indices and metabolic status in diabetic patients with depression: A randomized, controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-24</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58919</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Eligible volunteers will be randomly allocated (1:1:1) into one of the three following groups: (i) receiving an individualized anti-inflammatory diet with acupuncture therapy (n=30), (ii) receiving an individualized anti-inflammatory diet alone (iii) receiving common diet  (control group) (n=30). It is notable that volunteers will be randomized and allocated in each group based on the severity of depression (mild, moderate), age, and sex. The randomization will be carried out using an online system (https://www.sealedenvelope.com/). Once the randomization has been made, each patient is given a code with that she/he will be identified throughout the study. The randomization number will be assigned in a consecutive way. Randomization will not be exposed to those conducting the study and will be provided in sealed opaque envelopes with successive numbers. The envelope will be opened after signing the informed consent form and complying with the eligibility criteria by the patients.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 diabetes mellitus.</hc_freetext>
      <i_freetext>Intervention 1: An individualized anti-inflammatory diet with acupuncture therapy. All three groups will receive common treatment (medications, weight-loss diet in overweight and obese subjects, healthy dietary recommendations) throughout the study. dietary inflammatory index score in accordance to 24-h dietary recall and FFQ will be calculated. In general, considering pro- and anti- inflammatory food parameters and their food sources, participants’ characteristics, and an individualized anti-inflammatory diet will be prepared for both intervention groups. Our designed protocol for "Diabetic patients with Depression" emphasizes on treating different dimensions, etiologies, and symptoms of depression, and we will avoid those points which are proven to have blood sugar increasing effects. For instance, ST36 (ZuSanLi), ST25 (TianShu),etc, would not be punctured for diabetic patients. Intervention 2: َAn individualized anti-inflammatory diet alone. All three groups will receive common treatment (medications, weight-loss diet in overweight and obese subjects, healthy dietary recommendations) throughout the study. dietary inflammatory index score in accordance to 24-h dietary recall and FFQ will be calculated. In general, considering pro- and anti- inflammatory food parameters and their food sources, participants’ characteristics, and an individualized anti-inflammatory diet will be prepared for both intervention groups. Intervention 3: Common diet. All three groups will receive common treatment (medications, weight-loss diet in overweight and obese subjects, healthy dietary recommendations) throughout the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It is not clear release schedule.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nazli Namazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Endocrinology &amp; Metabolism Research Institute,  Shariati Hospital, North Kargar Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713137</zip>
        <telephone>+98 21 8863 1298</telephone>
        <email>nazli.namazi@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nazli Namazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Endocrinology &amp; Metabolism Research Institute,  Shariati Hospital, North Kargar Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713137</zip>
        <telephone>+98 21 8863 1298</telephone>
        <email>nazli.namazi@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Suffering from type 2 diabetes mellitus  for more than 6 months.
taking oral anti-diabetic medications
suffering from mild-to-moderate depression</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>injection of insulin or liraglutide
taking medicinal herbs or herbal medicine, antibiotics, antioxidant supplements (multivitamins &amp; minerals, vitamin E, vitamin C, Zinc),
suffering from severe depression, having chronic heart -vascular diseases, severe depression, chronic liver
chronic liver and kidney disease, uncontrolled thyroid and any other diabetes complications leads to inflammatory and oxidative conditions, other types of diabetes
taking psychiatry medications.
Pregnancy and lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>An individualized anti-inflammatory diet with acupuncture therapy. All three groups will receive common treatment (medications, weight-loss diet in overweight and obese subjects, healthy dietary recommendations) throughout the study. dietary inflammatory index score in accordance to 24-h dietary recall and FFQ will be calculated. In general, considering pro- and anti- inflammatory food parameters and their food sources, participants’ characteristics, and an individualized anti-inflammatory diet will be prepared for both intervention groups. Our designed protocol for "Diabetic patients with Depression" emphasizes on treating different dimensions, etiologies, and symptoms of depression, and we will avoid those points which are proven to have blood sugar increasing effects. For instance, ST36 (ZuSanLi), ST25 (TianShu),etc, would not be punctured for diabetic patients.</i_keyword>
      <i_keyword>َAn individualized anti-inflammatory diet alone. All three groups will receive common treatment (medications, weight-loss diet in overweight and obese subjects, healthy dietary recommendations) throughout the study. dietary inflammatory index score in accordance to 24-h dietary recall and FFQ will be calculated. In general, considering pro- and anti- inflammatory food parameters and their food sources, participants’ characteristics, and an individualized anti-inflammatory diet will be prepared for both intervention groups.</i_keyword>
      <i_keyword>Common diet. All three groups will receive common treatment (medications, weight-loss diet in overweight and obese subjects, healthy dietary recommendations) throughout the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depression. Timepoint: Baseline, after 8 weeks of the intervention (At the end of the intervention). Method of measurement: Montgomery-Asberg Depression Rating Scale (MADRS).</prim_outcome>
      <prim_outcome>Fat mass. Timepoint: Baseline, after 4 weeks of intervention and At the end of the intervention. Method of measurement: Bio-Electrical Impedance Analysis.</prim_outcome>
      <prim_outcome>Fat free mass. Timepoint: Baseline, after 4 weeks of intervention and At the end of the intervention. Method of measurement: Bio-Electrical Impedance Analysis.</prim_outcome>
      <prim_outcome>HbA1c. Timepoint: Baseline, At the end of the intervention. Method of measurement: Chromatography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Advanced glycation end products. Timepoint: Baseline, At the end of the intervention. Method of measurement: ELISA kit.</sec_outcome>
      <sec_outcome>FBS. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.</sec_outcome>
      <sec_outcome>Total cholesterol. Timepoint: Baseline,  At the end of the intervention. Method of measurement: Autoanalyzer.</sec_outcome>
      <sec_outcome>Low-density lipoprotein. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.</sec_outcome>
      <sec_outcome>High-density lipoprotein. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.</sec_outcome>
      <sec_outcome>High-sensitivity C-reactive protein. Timepoint: Baseline,  At the end of the intervention. Method of measurement: ELISA kit.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Development of Medical Research in Iran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-07</approval_date>
        <contact_name>National Institute for Medical Research Development</contact_name>
        <contact_address>Iran National Institute for Development of Medical Research (NIMAD), No. 21, beginning of Besat St., West Fatemi St., Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
